Application of RNAi to Genomic Drug Target Validation in Schistosomes

PLoS Neglected Tropical Diseases

Volumn 9, Issue 5, 2015, Pages

  Guidi, Alessandra ^a   Mansour, Nuha R ^a   Paveley, Ross A ^a   Carruthers, Ian M ^b   Besnard, Jérémy ^b   Hopkins, Andrew L ^b   Gilbert, Ian H ^b   Bickle, Quentin D ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; POLO LIKE KINASE 1; PRAZIQUANTEL; PROTEIN KINASE C; SMALL INTERFERING RNA; CALMODULIN; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE C BETA; PROTEIN SERINE THREONINE KINASE;

ADULT; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CULTURE OPTIMIZATION; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LARVAL DEVELOPMENT; MALE; MOUSE; NONHUMAN; PARASITE VIABILITY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SYNTHESIS; SCHISTOSOMIASIS; SCHISTOSOMULUM; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; ERYTHROCYTE; GENETICS; GENOMICS; PHYSIOLOGY; SCHISTOSOMA MANSONI;

ANIMALS; CALMODULIN; CELL CYCLE PROTEINS; DRUG DISCOVERY; ERYTHROCYTES; GENOMICS; HUMANS; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PRAZIQUANTEL; PROTEIN KINASE C BETA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; SCHISTOSOMA MANSONI;

EID: 84930672124     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003801     Document Type: Article

References (88)

1. Bethony J.M., et al., Can schistosomiasis really be consigned to history without a vaccine? Vaccine, 2008. 26(27–28): p. 3373–6.
2. Abath F.G., Development of vaccines against human parasitic diseases: tools, current status and perspectives. Expert Opin Investig Drugs, 2000. 9(2): p. 301–10. 11060678
3. McManus D.P., Loukas A., Current status of vaccines for schistosomiasis. Clin Microbiol Rev, 2008. 21(1): p. 225–42. doi: 10.1128/CMR.00046-07 18202444
4. Fenwick A., et al., The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008. Parasitology, 2009. 136(13): p. 1719–30. doi: 10.1017/S0031182009990400 19631008
5. Cioli D., Pica-Mattoccia L., Praziquantel. Parasitol Res, 2003. 90 Supp 1: p. S3–9. 12811543
6. Doenhoff M.J., Cioli D., Utzinger J., Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis, 2008. 21(6): p. 659–67. doi: 10.1097/QCO.0b013e328318978f 18978535
7. Doenhoff M.J., et al., Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology, 2009. 136(13): p. 1825–35. doi: 10.1017/S0031182009000493 19281637
8. Alonso D., et al., Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg, 2006. 74(2): p. 342–4. 16474094
9. Melman S.D., et al., Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis, 2009. 3(8): p. e504. doi: 10.1371/journal.pntd.0000504 19688043
10. Guisse F., et al., Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am J Trop Med Hyg, 1997. 56(5): p. 511–4. 9180600
11. Stelma F.F., et al., Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. American Journal of Tropical Medicine and Hygiene, 1995. 53(2): p. 167–70. 7677219
12. Cioli D., et al., Determination of ED50 values for praziquantel in praziquantel-resistant and—susceptible Schistosoma mansoni isolates. International Journal for Parasitology, 2004. 34(8): p. 979–87. 15217737
13. Black C.L., et al., Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop Med Int Health, 2009. 14(4): p. 450–7. doi: 10.1111/j.1365-3156.2009.02234.x 19222824
14. Botros S., et al., Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int J Parasitol, 2005. 35(7): p. 787–91. 15925597
15. Guidi A., et al., Praziquantel efficacy and long-term appraisal of schistosomiasis control in Pemba Island. Trop Med Int Health, 2010. 15(5): p. 614–8. doi: 10.1111/j.1365-3156.2010.02488.x 20214757
16. Ramirez B, B.Q. Yousif F, Fakorede FK, Mouries M-A, Nwaka S, Schistosomes: challenges in compound screening. Expert Opinion on Drug Discovery, 2007. 2: p. S53–361. doi: 10.1517/17460441.2.S1.S53 23489033
17. Sayed A.A., et al., Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med, 2008. 14(4): p. 407–12. doi: 10.1038/nm1737 18345010
18. Caffrey C.R., Secor W.E., Schistosomiasis: from drug deployment to drug development. Curr Opin Infect Dis, 2011. 24(5): p. 410–7. doi: 10.1097/QCO.0b013e328349156f 21734570
19. Berriman M., et al., The genome of the blood fluke Schistosoma mansoni. Nature, 2009. 460(7253): p. 352–8. doi: 10.1038/nature08160 19606141
20. Crowther G.J., et al., Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis, 2010. 4(8): p. e804. doi: 10.1371/journal.pntd.0000804 20808766
21. Oliveira G., The Schistosoma mansoni transcriptome: an update. Exp Parasitol, 2007. 117(3): p. 229–35. 17624328
22. Zerlotini A., et al., SchistoDB: a Schistosoma mansoni genome resource. Nucleic Acids Res, 2009. 37(Database issue): p. D579–82. doi: 10.1093/nar/gkn681 18842636
23. Verjovski-Almeida S., et al., Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nat Genet, 2003. 35(2): p. 148–57. 12973350
24. Stefanic S., et al., RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. PLoS Negl Trop Dis, 2010. 4(10): p. e850. doi: 10.1371/journal.pntd.0000850 20976050
25. Hopkins A.L., Groom C.R., The druggable genome. Nat Rev Drug Discov, 2002. 1(9): p. 727–30. 12209152
26. Dissous C., Grevelding C.G., Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? Trends Parasitol, 2011. 27(2): p. 59–66. doi: 10.1016/j.pt.2010.09.001 20920890
27. Fitzpatrick J.M., et al., Anti-schistosomal intervention targets identified by lifecycle transcriptomic analyses. PLoS Negl Trop Dis, 2009. 3(11): p. e543. doi: 10.1371/journal.pntd.0000543 19885392
28. Andrade L.F., et al., Eukaryotic protein kinases (ePKs) of the helminth parasite Schistosoma mansoni. BMC Genomics, 2011. 12: p. 215. doi: 10.1186/1471-2164-12-215 21548963
29. Aguero F., et al., Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov, 2008. 7(11): p. 900–7. doi: 10.1038/nrd2684 18927591
30. Boyle J.P., et al., Using RNA interference to manipulate endogenous gene expression in Schistosoma mansoni sporocysts. Mol Biochem Parasitol, 2003. 128(2): p. 205–15. 12742587
31. Geldhof P., et al., RNA interference in parasitic helminths: current situation, potential pitfalls and future prospects. Parasitology, 2007. 134(Pt 5): p. 609–19. 17201997
32. Krautz-Peterson G., et al., RNA interference in schistosomes: machinery and methodology. Parasitology, 2010. 137(3): p. 485–95. doi: 10.1017/S0031182009991168 19765345
33. Krautz-Peterson G., Skelly P.J., Schistosoma mansoni: the dicer gene and its expression. Exp Parasitol, 2008. 118(1): p. 122–8. 17707814
34. Ndegwa D., Krautz-Peterson G., Skelly P.J., Protocols for gene silencing in schistosomes. Exp Parasitol, 2007. 117(3): p. 284–91. 17870072
35. Magarinos M.P., et al., TDR Targets: a chemogenomics resource for neglected diseases. Nucleic Acids Res, 2012. 40(Database issue): p. D1118–27. doi: 10.1093/nar/gkr1053 22116064
36. Rojo-Arreola L., et al., Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS One, 2014. 9(1): p. e87594. doi: 10.1371/journal.pone.0087594 24489942
37. Faghiri Z., Skelly P.J., The role of tegumental aquaporin from the human parasitic worm, Schistosoma mansoni, in osmoregulation and drug uptake. FASEB J, 2009. 23(8): p. 2780–9. doi: 10.1096/fj.09-130757 19364765
38. Kasinathan R.S., Morgan W.M., Greenberg R.M., Genetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoni. PLoS Negl Trop Dis, 2011. 5(12): p. e1425. doi: 10.1371/journal.pntd.0001425 22163059
39. Kuntz A.N., et al., Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med, 2007. 4(6): p. e206. 17579510
40. Mourao M.M., et al., Phenotypic screen of early-developing larvae of the blood fluke, schistosoma mansoni, using RNA interference. PLoS Negl Trop Dis, 2009. 3(8): p. e502. doi: 10.1371/journal.pntd.0000502 19668375
41. Rinaldi G., et al., RNA interference targeting leucine aminopeptidase blocks hatching of Schistosoma mansoni eggs. Mol Biochem Parasitol, 2009. 167(2): p. 118–26. doi: 10.1016/j.molbiopara.2009.05.002 19463860
42. Skelly P.J., Da'dara A., Harn D.A., Suppression of cathepsin B expression in Schistosoma mansoni by RNA interference. Int J Parasitol, 2003. 33(4): p. 363–9. 12705930
43. Swierczewski B.E., Davies S.J., A schistosome cAMP-dependent protein kinase catalytic subunit is essential for parasite viability. PLoS Negl Trop Dis, 2009. 3(8): p. e505. doi: 10.1371/journal.pntd.0000505 19707280
44. Tran M.H., et al., Suppression of mRNAs encoding tegument tetraspanins from Schistosoma mansoni results in impaired tegument turnover. PLoS Pathog, 2010. 6(4): p. e1000840. doi: 10.1371/journal.ppat.1000840 20419145
45. Paveley R.A., et al., Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl Trop Dis, 2012. 6(7): p. e1762. doi: 10.1371/journal.pntd.0001762 22860151
46. Kamath R.S., et al., Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature, 2003. 421(6920): p. 231–7. 12529635
47. Bahia D., et al., Protein tyrosine kinases in Schistosoma mansoni. Mem Inst Oswaldo Cruz, 2006. 101 Suppl 1: p. 137–43. 17308761
48. Bahia D., et al., SmPKC1, a new protein kinase C identified in the platyhelminth parasite Schistosoma mansoni. Biochem Biophys Res Commun, 2006. 345(3): p. 1138–48. 16713993
49. Li L., Stoeckert C.J., Jr.Roos D.S., OrthoMCL: identification of ortholog groups for eukaryotic genomes. Genome Res, 2003. 13(9): p. 2178–89. 12952885
50. Camacho C., et al., BLAST+: architecture and applications. BMC Bioinformatics, 2009. 10: p. 421. doi: 10.1186/1471-2105-10-421 20003500
51. Chen F., et al., Assessing performance of orthology detection strategies applied to eukaryotic genomes. PLoS One, 2007. 2(4): p. e383. 17440619
52. Nidhi et al., Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model, 2006. 46(3): p. 1124–33. 16711732
53. Gaulton A., et al., ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res, 2012. 40(Database issue): p. D1100–7. doi: 10.1093/nar/gkr777 21948594
54. Ertl P., Rohde B., Selzer P., Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem, 2000. 43(20): p. 3714–7. 11020286
55. Rogers D., Hahn M., Extended-connectivity fingerprints. J Chem Inf Model, 2010. 50(5): p. 742–54. doi: 10.1021/ci100050t 20426451
56. Rogers D.J., Tanimoto T.T., A Computer Program for Classifying Plants. Science, 1960. 132(3434): p. 1115–8. 17790723
57. Shannon P., et al., Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003. 13(11): p. 2498–504. 14597658
58. Basch P.F., Humbert R., Cultivation of Schistosoma mansoni in vitro. III. implantation of cultured worms into mouse mesenteric veins. J Parasitol, 1981. 67(2): p. 191–5. 7241279
59. Mann V.H., et al., Culture for genetic manipulation of developmental stages of Schistosoma mansoni. Parasitology, 2010. 137(3): p. 451–62. doi: 10.1017/S0031182009991211 19765348
60. Kines K.J., et al., Integration of reporter transgenes into Schistosoma mansoni chromosomes mediated by pseudotyped murine leukemia virus. FASEB J, 2008. 22(8): p. 2936–48. doi: 10.1096/fj.08-108308 18403630
61. Basch P.F., Cultivation of Schistosoma mansoni in vitro. I. Establishment of cultures from cercariae and development until pairing. J Parasitol, 1981. 67(2): p. 179–85. 7241277
62. Boissier J., Durand P., Mone H., PCR effectiveness for sexing Schistosoma mansoni cercariae: application for sexing clonal cercarial populations. Mol Biochem Parasitol, 2001. 112(1): p. 139–41. 11166395
63. Correnti J.M., Brindley P.J., Pearce E.J., Long-term suppression of cathepsin B levels by RNA interference retards schistosome growth. Mol Biochem Parasitol, 2005. 143(2): p. 209–15. 16076506
64. Krautz-Peterson G., et al., Optimizing gene suppression in schistosomes using RNA interference. Mol Biochem Parasitol, 2007. 153(2): p. 194–202. 17420062
65. Livak K.J., Schmittgen T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 402–8. 11846609
66. Doenhoff M., et al., Factors affecting the acquisition of resistance against Schistosoma mansoni in the mouse. I. Demonstration of resistance to reinfection using a model system that involves perfusion of mice within three weeks of challenge. J Helminthol, 1978. 52(3): p. 173–86. 722037
67. Hillier L.W., et al., Genomics in C. elegans: so many genes, such a little worm. Genome Res, 2005. 15(12): p. 1651–60. 16339362
68. Caffrey C.R., et al., A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One, 2009. 4(2): p. e4413. doi: 10.1371/journal.pone.0004413 19198654
69. Valentim C.L., et al., Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. Science, 2013. 342(6164): p. 1385–9. doi: 10.1126/science.1243106 24263136
70. Gobert G.N., et al., Transcriptional changes in Schistosoma mansoni during early schistosomula development and in the presence of erythrocytes. PLoS Negl Trop Dis, 2010. 4(2): p. e600. doi: 10.1371/journal.pntd.0000600 20161728
71. Dissous C., Grevelding C.G., Long T., Schistosoma mansoni Polo-like kinases and their function in control of mitosis and parasite reproduction. An Acad Bras Cienc, 2011. 83(2): p. 627–35. 21670883
72. LoVerde P.T., et al., Schistosoma mansoni genome project: an update. Parasitol Int, 2004. 53(2): p. 183–92. 15081950
73. Zou X., et al., RNAi silencing of calcium-regulated heat-stable protein of 24 kDa in Schistosoma japonicum affects parasite growth. Parasitol Res, 2011. 108(3): p. 567–72. doi: 10.1007/s00436-010-2099-0 21085993
74. Katsumata T., et al., Hatching of Schistosoma mansoni eggs is a Ca2+/calmodulin-dependent process. Parasitol Res, 1989. 76(1): p. 90–1. 2622901
75. Kawamoto F., et al., Possible roles of cAMP and Ca2+ in the regulation of miracidial transformation in Schistosoma mansoni. Parasitol Res, 1989. 75(5): p. 368–74. 2542928
76. Taft A.S., Yoshino T.P., Cloning and functional characterization of two calmodulin genes during larval development in the parasitic flatworm Schistosoma mansoni. J Parasitol, 2011. 97(1): p. 72–81. doi: 10.1645/GE-2586.1 21348610
77. Krautz-Peterson G., et al., Suppressing glucose transporter gene expression in schistosomes impairs parasite feeding and decreases survival in the mammalian host. PLoS Pathog, 2010. 6(6): p. e1000932. doi: 10.1371/journal.ppat.1000932 20532163
78. Yarden Y., Sliwkowski M.X., Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2001. 2(2): p. 127–37. 11252954
79. Ludtmann M.H., et al., Protein kinase C signalling during miracidium to mother sporocyst development in the helminth parasite, Schistosoma mansoni. Int J Parasitol, 2009. 39(11): p. 1223–33. doi: 10.1016/j.ijpara.2009.04.002 19394337
80. Mansour N.R., Bickle Q.D., Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. PLoS Negl Trop Dis, 2010. 4(8): p. e795. doi: 10.1371/journal.pntd.0000795 20706580
81. Laggner C., et al., Chemical informatics and target identification in a zebrafish phenotypic screen. Nat Chem Biol, 2012. 8(2): p. 144–6.
82. Archambault V., Glover D.M., Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol, 2009. 10(4): p. 265–75. doi: 10.1038/nrm2653 19305416
83. Long T., et al., Schistosoma mansoni Polo-like kinase 1: A mitotic kinase with key functions in parasite reproduction. Int J Parasitol, 2010. 40(9): p. 1075–86. doi: 10.1016/j.ijpara.2010.03.002 20350550
84. Long T., et al., SmSak, the Second Polo-Like Kinase of the Helminth Parasite Schistosoma mansoni: Conserved and Unexpected Roles in Meiosis. PLoS One, 2012. 7(6): p. e40045. doi: 10.1371/journal.pone.0040045 22768216
85. Brumlik M.J., et al., Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication. Exp Parasitol, 2011. 128(2): p. 170–5. doi: 10.1016/j.exppara.2011.02.016 21338604
86. Wei S., et al., Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. Int J Parasitol, 2002. 32(8): p. 969–77. 12076626
87. Ressurreicao M., et al., A role for p38 MAPK in the regulation of ciliary motion in a eukaryote. BMC Cell Biol, 2011. 12: p. 6. doi: 10.1186/1471-2121-12-6 21269498
88. Ressurreicao M., et al., A role for p38 mitogen-activated protein kinase in early post-embryonic development of Schistosoma mansoni. Mol Biochem Parasitol, 2011. 180(1): p. 51–5. doi: 10.1016/j.molbiopara.2011.07.002 21787807